The goal of the 2018 Clinical Hepatology Update is to allow medical professionals the opportunity to review the up-to-date diagnosis and management of a variety of liver diseases with experts and leaders in the field of Hepatology. This course will also cover ongoing research in a variety of liver related topics which will potentially have significant impact on the future practice of Clinical Hepatology. The content features academic leaders in Hepatology who are actively contributing to these advances.
- Patient-centered Care
- Work in Interdisciplinary Teams
- Evidence-based Practice
- Quality Improvement
- Patient Care
- Medical Knowledge
- Practice Based Learning and Improvement
- Cognitive Expertise
- Hari S. Conjeevaram, MD, MS
- Coleman I. Smith, MD, FAASLD
- Elizabeth K. Goacher, PA-C, MHS
- April G. Morris, FNP
- Listen to 6 self-directed recorded sessions (90 - 135 minutes in length) while following along with visual slides
- Take a post-activity quiz for each session
- Answer evaluation questions
All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.
Release Date: September 20, 2018
Expiration Date: September 19, 2020
Copyright: All faculty in this activity have given their permission for publication OR ©2018 AASLD
Hari Conjeevaram (Moderator)
Coleman I. Smith (Moderator)
Elizabeth K. Goacher (Moderator)
Zobair M. Younossi
Zobair M Younossi is the President of Inova Medicine as well as Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Falls Church, Virginia, USA. He is also Chair of Clinical Research, Inova Health System, Falls Church, Virginia. Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry (Alpha Omega Alpha 1989) in Rochester, NY, USA. He then completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California, USA, while earning his master of public health degree with multiple honours from San Diego State University School of Public Health, San Diego, California, USA. He served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio, USA, before establishing the Canter for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to outcomes research in liver disease and clinical, health services and translational research in non-alcoholic fatty liver disease (NAFLD). He has served as Vice President of Research for Inova Health System and currently serves as the Chair of Research for Inova Health System. He also serves as the President and Chairman of the Board of Trustees of the Chronic Liver Disease Foundation (2018-Present) and the Board of Inova Health System Foundation (2011-Present). He was appointed by Governors T Kaine and B McDonnell of Virginia to the Board of Directors of Virginia Biotechnology Research Partnership Authority (2008-2014). He also served Virginia Tobacco & Health Research Repository (VTHRR), Board of Directors, America Heart Association, Mid-Atlantic Affiliate (2010-2012) and Board of the American College of Gastroenterology Institute for Clinical Research & Education (2013-Present). Finally, he has served on multiple committees for American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastrointestinal Association and George Mason University as well as numerous committees at Inova Fairfax Medical Campus and Inova Health System.
Over the past 3 decades, Dr. Younossi has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of Global NASH Council and the Global Liver and NASH Registries. His research in both NAFLD and outcomes research is highly cited and he a highly sought-after speaker for National and International Scientific meetings. In addition to research and administrative duties, Dr. Younossi has been actively involved in teaching patients (through America Liver Foundation) students (Both medical students and post graduate students), residents and GI/Hepatology fellows. He has also served as Chair, Director or faculty of a number international scientific and CME related courses. He is also the Chair of the Global NASH Council and Global NASH Registry.
Dr. Younossi specializes in hepatology and gastroenterology and has authored over 560 articles, 3 books, 6 journal supplements, over 25 book chapters and over 900 abstracts at the international scientific meetings. He is highly sought-after speaker providing over 430 faculty lectures in national and international meetings. His academic productivity has led to an H-index of 88. Dr.Younossi has also served as the co-editor of Liver International, Associate Editor of J of Hepatology and on the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.
Robert J. Fontana
Victor J. Navarro
Victor J. Navarro, MD, MHCM, FAASLD earned his Doctor of Medicine degree from the Pennsylvania State College of Medicine and completed medical residency followed by chief residency in Internal Medicine at Temple University. Thereafter, he obtained fellowship training in Gastroenterology, Hepatology, and Hepatobiliary Endoscopy at Yale University. In 1994, Dr. Navarro joined the faculty of the Yale University School of Medicine as an Assistant Professor of Medicine and Epidemiology and the Director of its Liver Failure and Transplantation service. He was also the Director of the State of Connecticut Emerging Infections Program Liver Study Unit. His scholarly work while at Yale focused on the population-based epidemiology of chronic liver disease. In 2019, Dr. Navarro earned his Masters in Healthcare Management from Harvard University.
As a mentor, Dr. Navarro has been directly responsible for the scholarly and clinical training of many young and mid-career health professionals and academicians. Dr. Navarro’s chief sources of research funding are the National Institutes of Health as an investigator for the U.S. Drug Induced Liver Injury Network (DILIN), and the Patient Centered Outcomes Research Institute for his study of Palliative Care in Patients with End Stage Liver Disease.
Amol S. Rangnekar
Jessica L. Mellinger
Stephen H. Caldwell
Dr. Stephen Caldwell is a hepatologist specializing in a nonalcoholic steatohepatitis (NASH), including its relationship to so-called cryptogenic cirrhosis, ethnic and familial relationships and the role of mitochondrial dysfunction in the disease. He and his colleagues pioneered work on cellular ballooning and the role of small fat droplets in NASH and have also worked extensively with cyanoacrylates in the treatment of gastric variceal bleeding. He is overseeing a number of treatment trials for NASH and related liver fibrosis and is closely involved with a network of physicians and scientists working with coagulation disorders in liver disease. In 1992, he joined the faculty at UVA, helping to develop the hepatology program. Now a professor of medicine in the Division of Gastroenterology and Hepatology at UVA, Dr. Caldwell is board-certified in internal medicine and gastroenterology.
Elliot B. Tapper
Dr. Elliot Tapper is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.
Matthew R. Kappus
April G. Morris
Catherine Frenette is the Medical Director of Liver Transplant at the Scripps Center for Organ Transplant, Scripps Green Hospital, La Jolla, CA. She is also the Medical Director of the Liver and Hepatocellular Cancer Program at the Scripps MD Anderson Cancer Center. Catherine underwent medical training at Rush Medical College in Chicago, IL. She then completed internal medicine training at Scripps Mercy Hospital in San Diego, CA, and subsequently underwent training in gastroenterology with a focus on transplant hepatology at Scripps Clinic in La Jolla, CA. Since joining Scripps in 2012, Catherine has worked diligently to provide excellent medical care to patients with end stage liver disease and liver cancer. In addition to directing two major medical programs in Southern California, Catherine has been the Principle or Co-Investigator for multiple clinical trials related to liver disease and liver cancer. She also serves a key role in the training of gastroenterology fellows, as well as internal medicine residents. Catherine has also served the community through the American Liver Foundation, where she serves as vice-chair of the local Medical Advisory Committee and is also on the National Executive Committee. She has been awarded Fellow Status of the American Society of Transplantation and has also been awarded Fellow of the American Gastroenterology Association.
I have worked diligently in the transplant world for more than a decade, where I have been active in local and regional meetings, attending nearly every regional meeting in the past 12 years. I also have been active in meetings regarding policy, attending national meetings to discuss liver redistricting and participating in the American Transplant Society Liver and Intestinal Community of Practice Policies Subcommittee. I have a unique perspective regarding transplantation, because I am also a donor family member. This allows me to truly understand all parties involved in transplant, including the donor, the recipient, as well as the transplant programs and organ procurement organizations. I have served on many committees throughout my career and am committed to continuing to serve the transplant community as an Associate Councillor.
Norah A. Terrault
Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.
Michael B. Fallon
Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.
Mitchell L. Shiffman
Nancy S. Reau
Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal. She was one of the original authors of the AASLD/IDSA hepatitis C guidance document. She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.
Upon completion of this activity, learners will be able to:
- Discuss the management of patients with a variety of common problems in liver disease.
- Become familiar with ongoing advances in hepatology and their potential application to clinical practice.
- Implement evidence-based treatment in a variety of liver diseases
- Nurse Practitioners
- Physician Assistants
- Transplant Coordinators
- Other physicians Specify: Primary care MDs
- Other healthcare professionals Specify: Clinical researchers in the field of liver disease
Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.
Accreditation Statement The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation AASLD designates this enduring activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
American Board of Internal Medicine (ABIM) MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pediatrics (ABP) MOC Statement
“Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 12.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”
MOC Points Process
Physicians seeking MOC points must complete the CME evaluation in addition to viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 12.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
The organizers and faculty have reported the following disclosures:
Hari S. Conjeevaram, MD, MS
Nothing to disclose
Elizabeth K. Goacher, PA-C, MHS
Advisory Boards and/or Review Panels: AbbVie Pharmaceuticals, Gilead Pharmaceuticals
Speakers' Bureau: AbbVie Pharmaceuticals; Gilead Pharmaceuticals
Robert J. Fontana, MD, FAASLD
Consulting: Alynam Pharmaceuticals
Grants/Research Support: BMS, Gilead, Abbvie
Victor J. Navarro , MD, FAASLD
Nothing to disclose
Lindsay Y. King, MD
Nothing to disclose
Amol S. Rangnekar, MD
Nothing to disclose
Michael B. Fallon, MD, FAASLD
Nothing to disclose
Stephen H. Caldwell, MD, FAASLD
Advisory Committees or Review Panels: Gencia
Grants/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM, Mallinckrodt, Conatus, Galmed
Elliott B. Tapper, MD
Grants/Research Support: Valeant, Gilead
Matthew R. Kappus, MD
Nothing to disclose
Jessica Mellinger, MD
Grants/Research Support: Salix Pharmaceuticals
April G. Morris , FNP
Advisory Boards and/or Review Panels: AbbVie, Inc., Merck & Co.
Speakers' Bureau: Gilead, AbbVie, Inc.
Zobair M. Younossi , MD, MPH, FAASLD
Advisory Boards and/or Review Panels: Gilead, BMS, Intercept, Abbvie and GSK
Consulting: Gilead, Intercept
Cynthia A. Moylan, MD
Grants/Research Support: TaiwanJ Pharmeceuticals, Madrigal Pharmaceuticals, Conatus
Mishal Mendiratta-Lala, MD
Nothing to disclose
Christine Hsu, MD
Nothing to disclose
Catherine T. Frenette, MD
Advisory Boards and/or Review Panels: Bayer, Intercept
Speakers' Bureau: Bayer, Gilead
Puneeta Tandon, MD, FRCP
Nothing to disclose
Mitchell L. Shiffman, MD, FAASLD
Advisory Boards and/or Review Panels: Abbvie, BMS, Gilead, Intercept, Merck, Salix
Grants/Research Support: Abbvie, BMS, Conatus, CymaBay, Exalenz, Galectin, Genfit, Intercept, Immuron, Merck, NGMBio, Novartis, Shire
Speakers' Bureau: Abbvie, Bayer, BMS, Daiichi Sankyo, Gilead, Intercept, Merck
Nancy Reau, MD, FAASLD
Advisory Boards and/or Review Panels: AbbVie
Consulting: Gilead, Abbott, Merck
Coleman I. Smith, MD, FAASLD
Adisory Board and/or Review Panels: BMS, Dova
Grants/Research Support: Promethius, Genfit, Intercept, Conatus, Gilead, Abbvie, BMS
Speakers' Bureau: Gilead, Abbvie
Norah Terrault, MD, PhD
Advisory Committees or Review Panels: Merck, Intercept, Conatus; Consulting: CCO Hepatitis, Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc.
Grants/Research Support: AbbVie, Biotest, Eisai, Gilead, BMS, Merck, Allergan
Nothing to disclose
Sheryl Morgan, CE Coordinator
Nothing to disclos
Acknowledgement of Financial or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.